UNSPSC 51471703: Boric acid

This classification denotes a topical anti-infective agent with the molecular formula BH3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R57ZHV85D4, chemically known as boric acid, crude natural, containing not more than 85 per cent ofh3bo3 calculated on the dry weight but generally known as boric acid, which bears US NIH Compound Identifier 7628. European Medicines Agency schedules Boric acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12471MIG.

World Health Organization schedules boric acid in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, BORIC ACID remains the US FDA Preferred Term for this commodity. Boric acid bears US NLM identifiers UMLS ID C0006020 and NCI Concept Code C47416. SMILES: B(O)(O)O.

UNSPSC 51471703 Boric acid (Commodity) appears in recent state and local solicitations primarily as a component within broader janitorial and pharmaceutical supply contracts rather than as a standalone procurement item. The code shows limited direct activity focused exclusively on boric acid; instead, state and local jurisdictions are sourcing the chemical as part of multi-line consumable supplies for operational use in fire rescue facilities and as a potential ingredient or formulation component in generic over-the-counter (OTC) pharmaceutical products distributed through cooperative purchasing agreements.

Hillsborough County Board of County Commissioners issued an ITB on July 7, 2026 (due July 24, 2026) for consumable janitorial and operational supplies estimated at $765,679.84 annually to support 47 fire stations operated 24 hours daily by Hillsborough County Fire Rescue in Tampa, Florida; boric acid would fall within this broader supplies category. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026. Both solicitations emphasize authorized distributor relationships, FDA compliance (where applicable), cGMP certification, and wholesale supply-chain partnerships. The geographic spread appears concentrated in Florida (Hillsborough County) and the Upper Midwest and Pacific Northwest through MMCAP's multistate cooperative vehicle. No solicitations in the recent-opportunities block are framed as standalone boric acid procurements; the code shows activity only as an incidental line item within larger consumable-supply or pharmaceutical-formulation contracts.